Verici Dx PLC
Company Profile
Business description
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Contact
19 Stanwell Road
Avon House
Penarth
CardiffCF64 2EZ
GBRT: +44 2920710570
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,006.80 | 116.00 | 1.30% |
CAC 40 | 7,822.67 | 0.67 | 0.01% |
DAX 40 | 24,289.51 | 81.42 | -0.33% |
Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
FTSE 100 | 8,992.12 | 19.48 | 0.22% |
HKSE | 24,825.66 | 326.71 | 1.33% |
NASDAQ | 20,895.65 | 10.01 | 0.05% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
S&P 500 | 6,296.79 | 0.57 | -0.01% |
S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
SSE Composite Index | 3,534.48 | 17.66 | 0.50% |